CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 138 enrolled
Drug / intervention
Endostar +1 moredrug
Likely dose
Endostar 7.5mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00912392
NCT00912392Phase 2Completed
CompareCT.gov

Etoposide-Carboplatin (EC) Versus EC Plus Endostar in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC): Randomized, Open Label, Placebo-controlled, Multicentre Study

Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd·interventional·Posted Jun 3, 2009·Updated Sep 3, 2014

In Brief

A Phase 2 clinical trial evaluating Endostar and Etoposide-Carboplatin for Small Cell Lung Cancer. Completed, enrolled 138 participants across 1 site.

Detailed Summary

Background: The effect of existing treatment modalities of extensive disease small-cell lung cancer (ED-SCLC) is unsatisfactory. Progress of new strategies including more efficient therapy is wanted. Endostar® (Rh-endostatin Injection) may have anti-tumor activity by against vascular endothelial growth factor for initial treatment. This study was designed to evaluate the safety and efficacy of Endostar® combined with etoposide-carboplatin (EC) chemotherapy in patients with ED-SCLC seeking for more effective treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 3, 2009
Enrollment StartMay 1, 2009
Primary CompletionDec 1, 2012
TodayJul 1, 2026
Enrollment to primary: 3.6 yearsPosted 17.1 years ago

Interventions

Endostardrug

Endostar® 7.5mg/m2 on day 1 to day 14

Etoposide-Carboplatindrug

Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.